Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen

27 May 2012

At its regular monthly meeting last week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a number of positive opinions on new medicinal products, including the following:

• Spanish drug major Almirall’s (ALM: MC) aclidinium bromide (trade names Bretaris Genuair and Eklira Genuair, as maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease;

• Japan’s Eisai’s (TYO: 4523) Fycompa (perampanel) as adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older;

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical